Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Audrey Lastra

Physician Assistant, Medical New Haven, CT Physician Assistant

NPI 1104105600 CMS profile 10571933

1450 Chapel St, New Haven, CT 06511

Open in the dashboard

General payments

$13,174

406 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Audrey Lastra of New Haven, CT is reported in the CMS Open Payments database as having received $13,174 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,625 122
2024 General $3,930 145
2023 General $2,058 87
2022 General $1,165 36
2021 General $395 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Audrey Lastra
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Audrey Lastra were reported at $5,625. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Audrey Lastra Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $395 $156 $41–$563 $132
2022 $1,165 $185 $55–$649 $149
2023 $2,058 $199 $58–$717 $160
2024 $3,930 $206 $62–$740 $164
2025 $5,625 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,749 35 payments
  2. AbbVie, Inc. $1,968 90 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,185 40 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,011 35 payments
  5. Madrigal Pharmaceuticals $897 10 payments
  6. Phathom Pharmaceuticals, Inc. $771 27 payments
  7. Ardelyx, Inc. $611 27 payments
  8. Genzyme Corporation $606 18 payments
  9. Celgene Corporation $448 16 payments
  10. Gilead Sciences, Inc. $415 15 payments
  11. Other $2,512 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,408 400 payments
  2. Consulting Fee $1,560 1 payment
  3. Education $206 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,355 21 payments
  2. XIFAXAN $866 26 payments
  3. ENTYVIO $821 27 payments
  4. REZDIFFRA $686 7 payments
  5. RINVOQ $619 29 payments
  6. IBSRELA $611 27 payments
  7. LINZESS $589 36 payments
  8. STELARA $571 17 payments
  9. ZEPOSIA $567 18 payments
  10. VOQUEZNA $554 15 payments
  11. Other $6,022 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,061

Median for Physician Assistant: 241

Drug cost

$269,408

Median for Physician Assistant: $4,110

Branded share of claims

31.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 15 $72,362
Linzess Linaclotide Brand 45 $53,300
Ibsrela Tenapanor Hcl Brand 16 $46,346
Trulance Plecanatide Brand 29 $21,260
Voquezna Vonoprazan Fumarate Brand 18 $18,533
Dexlansoprazole Dr Dexlansoprazole Brand 21 $8,961
Mesalamine Generic 24 $8,321
Esomeprazole Magnesium Generic 55 $5,995
Omeprazole Generic 265 $4,858
Budesonide Dr Budesonide Brand 12 $4,504

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$29,543

Medicare's payments for the services billed

Medicare patients

207

Average age 75

Services billed

908

130 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 34%
Chronic kidney disease 31%
Depression 31%
Osteoporosis 26%
Diabetes 25%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $344
$344 18 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $336
$336 — —
DUPIXENT
  • GENZYME CORPORATION $310
  • Regeneron Healthcare Solutions, Inc. $23
$332 — —
SKYRIZI
  • AbbVie, Inc. $300
$300 — —
TREMFYA
  • Janssen Biotech, Inc. $278
$278 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record